FFM
AXSM icon

Fairmount Funds Management’s Axsome Therapeutics AXSM Stock Holding History

Fairmount Funds Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-600,000
Closed -$26.8M – 20
2022
Q3 		$26.8M Buy
+600,000
New +$30M 4.71% 10

Other funds holding AXSM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fairmount Funds Management's AXSM Position: Q4 2025 in Review

Fairmount Funds Management sold out of Axsome Therapeutics (AXSM) in Q4 2025, closing a stake of 815,176 shares — an estimated $99M sold.

Fairmount Funds Management first reported a position in AXSM in Q1 2020 and held it in 23 quarters. The position peaked at $212M in Q3 2024. 398 funds tracked by Wall St. Rank hold AXSM as of Q4 2025.

  • Fairmount Funds Management reported no remaining Axsome Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Fairmount Funds Management sold 815,176 Axsome Therapeutics shares in Q4 2025, an estimated $99M.
  • Fairmount Funds Management first reported a position in Axsome Therapeutics in Q1 2020 and held it in 23 quarters.
  • Fairmount Funds Management's Axsome Therapeutics position peaked at $212M in Q3 2024.
  • 398 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q4 2025.

Based on Fairmount Funds Management's 13F filing for Q4 2025, filed 17 Feb 2026.